Johnson & Johnson (JNJ) says it has "no intention to bid statement for Horizon Therapeutics" (HZNP). According to a statement by the company, "Further to the announcement by Horizon on November 29, 2022, Janssen Global Services, confirmed today that it does not intend to make an offer for Horizon. Accordingly, the company will be bound by the restrictions set out in Rule 2.8 of the Irish Takeover Rules."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- Yumanity declares special dividend related to asset sale, merger with Kineta
- J&J says won’t make offer for Horizon Therapeutics, Bloomberg reports
- Needham healthcare analyst to hold an analyst/industry conference call
- Horizon Therapeutics price target raised to $125 from $101 at Jefferies
- Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley